Richter sharpens ovarian aging focus following Celmatix asset deal
Gedeon Richter acquired Celmatix's women's health discovery portfolio, adding early-stage programs in infertility, endometriosis and ovarian aging. The assets include a first-in-class oral FSH receptor agonist, a JNK inhibitor for endometriosis and early-stage AMH-targeting antibodies, signaling Richter's push to integrate reproductive aging biology into its drug-development platform.
Why it mattersGedeon Richter acquired Celmatix's portfolio including an oral FSH agonist and AMH antibodies, prompting accelerated clinical funding and.
People Mentioned
Kyle Umipig